<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1296">
  <stage>Registered</stage>
  <submitdate>14/09/2006</submitdate>
  <approvaldate>14/09/2006</approvaldate>
  <nctid>NCT00377598</nctid>
  <trial_identification>
    <studytitle>Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia</studytitle>
    <scientifictitle>A Phase 2, Double Blind, Placebo Controlled, Dose-Ranging Study in Subjects With Postherpetic Neuralgia (PHN) to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Four Doses of TAK-583, Compared With Placebo</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2005-005863-26</secondaryid>
    <secondaryid>TAK-583-EC201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuralgia, Postherpetic</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TAK-583
Treatment: drugs - TAK-583
Treatment: drugs - TAK-583
Treatment: drugs - TAK-583
Treatment: drugs - Placebo

Experimental: TAK-583 5 mg QD - 

Experimental: TAK-583 25 mg QD - 

Experimental: TAK-583 50 mg QD - 

Experimental: TAK-583 100 mg QD - 

Placebo Comparator: Placebo QD - 


Treatment: drugs: TAK-583
TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks

Treatment: drugs: TAK-583
TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks

Treatment: drugs: TAK-583
TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks

Treatment: drugs: TAK-583
TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks

Treatment: drugs: Placebo
TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change from Baseline in average daily pain intensity score for the previous 7 days</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline to each study visit in average daily pain intensity score for the last 7 days</outcome>
      <timepoint>At All Visits</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in pain assessment as assessed by Short form McGill Pain Questionnaire</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in weekly mean sleep interference scores (assessed on an 11-point numerical scale in the subject's sleep diary)</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinician and subject global impression of change using a 7-point scale</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in quality of life as assessed by Short Form-36</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in Profile of Mood States</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of subjects with at least 30% and 50% reduction from baseline in average daily pain intensity score</outcome>
      <timepoint>Week 8 or Final Visit</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male and female subjects with postherpetic neuralgia whose pain has been present for
             &gt;3 months following healing of the herpes zoster rash.

          -  Subjects with an mean pain intensity score of 4 or more (determined from at least 4
             daily recordings of pain intensity on an 11-point numerical scale over the preceding 7
             days) during the baseline phase.

          -  Subjects aged 50 years and above.

          -  The female subject is not of child-bearing potential (eg, sterilized, postmenopausal).</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Malignancy within the past 2 years with the exception of basal cell carcinoma.

          -  Subjects who have undergone neurolytic or neurosurgical therapy for postherpetic
             neuralgia.

          -  Clinically significant, actively treated or unstable hepatic, biliary, respiratory,
             renal, rheumatologic, or hematologic illnesses, or unstable cardiovascular disease as
             assessed by the investigator.

          -  WBC less than 2500, ANC less than 1500, platelets less than 100,000; ALT, AST or
             alkaline phosphatase greater than 1.5x ULN; total bilirubin greater than or equal to
             1.2 times the upper limit of normal (excluding Gilbert's Disease); predicted GFR using
             Cockcroft and Gault formula less than or equal to 40 mL/min.

          -  Subjects with greater than 5 red blood cells per high-power field on urinalysis.

          -  Subjects with an albumin/creatinine ratio in an untimed ("spot") morning urine
             specimen greater than the upper limit of normal.

          -  Subjects who are immunocompromised or have clinically significant haematological
             abnormalities.

          -  Subjects with a history of HIV infection.

          -  Subjects with a positive hepatitis panel (including hepatitis B surface antigen,
             antibody to hepatitis B core antigen, antibody to hepatitis B surface antigen, or
             antibody to hepatitis C virus), except subjects with positive antibodies to hepatitis
             B surface antigen who have received hepatitis B vaccination and who have no history of
             serological evidence of liver disease.

          -  Subjects having other severe pain which may impair the self assessment of the pain due
             to postherpetic neuralgia.

          -  Subjects who have participated in a clinical trial for an investigational drug and/or
             agent within 30 days prior to baseline.

          -  Subjects who have received TAK-583 in a previous clinical study.

          -  Subjects who have donated more than 400 mL of blood in the 90 days prior to the
             beginning of the study.

          -  Subjects who have a history of alcohol or illicit drug abuse in the past 2 years

          -  Clinically significant abnormal 12 lead electrocardiogram, including QT interval
             corrected for heart rate greater than 450 ms that is confirmed on a repeat
             electrocardiogram.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>399</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital> - Sydney</hospital>
    <hospital> - Kipparing</hospital>
    <hospital> - Maroochydore</hospital>
    <hospital> - Box Hill</hospital>
    <hospital> - Carlton</hospital>
    <hospital> - Fitzroy</hospital>
    <hospital> - Perth</hospital>
    <postcode> - Sydney</postcode>
    <postcode> - Kipparing</postcode>
    <postcode> - Maroochydore</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Carlton</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Hradec Kralove</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Moravska Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Goerlitz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Magdeburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwerin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Arnhem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Breda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Roosendaal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Stadskanaal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mosina k/Poznania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Free State</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kwa-Zulu Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Mpumalanga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chichester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Darlington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Plymouth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Solihull</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Takeda</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy of TAK-583, once daily (QD), in
      relieving pain in subjects with postherpetic neuralgia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00377598</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>VP Clinical Science</name>
      <address>Takeda Global Research &amp; Development Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>